Autolus is growing revenue 118% YoY from a small base but burns cash at -171% of revenue, trades in a downtrend near $1.54, and has no usable analyst target after the raw figure was rejected as implausible.
Thesis pillars
- Cash Burn Funding Risk→Stable
- Rapid Revenue Growth→Stable
- Downtrend Pullback↑Improving
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Oct 24, 2026, based on the 10-K filed Mar 27, 2026
Autolus Therapeutics plc (AUTL) Stock Analysis
Range Bound setup · Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $1.63: Quality below floor (2.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.7/10. Specifically: Below-average business quality; Below long-term trend.
Autolus Therapeutics markets AUCATZYL (obe-cel), a CD19-targeted CAR T cell therapy for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia, approved by the FDA in November 2024 and launched in the U.S. in January 2025, with the UK's MHRA and the European... Read more
Sell if holding. Engine safety override at $1.63: Quality below floor (2.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.7/10. Specifically: Below-average business quality; Below long-term trend. Chart setup: RSI 41 mid-range, Bollinger mid-band. Score 5.7/10, moderate confidence.
Passes 6/9 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
Recent developments
updated 2026-10-29Recent Developments — Autolus Therapeutics plc
Latest news
- NEWS Autolus Therapeutics to Report Third Quarter 2026 Financial Results on November 10, 2026 — fiscal.ai Oct 27, 2026
- NEWS Autolus Therapeutics Published Abstract Filed TO American College Of Rheumatology Convergence 2026 — benzinga Oct 5, 2026 positive
- NEWS The FDA Grants Regenerative Medicine Advanced Therapy Designation to Autolus Therapeutics' Obecabtagene Autoleucel for S — benzinga Sep 9, 2026 positive
- NEWS Autolus Therapeutics Affirms FY2026 Sales Guidance of $140.000M-$150.000M vs $136.669M Est — benzinga Aug 11, 2026 positive
- NEWS Autolus Therapeutics Q2 EPS $(0.15) Beats $(0.23) Estimate, Sales $45.689M Beat $34.016M Estimate — benzinga Aug 11, 2026 positive
Generated 2026-10-29T11:14:31Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Clinical-stage biotech: losses expected pre-commercialisation. Quality floor doesn't distinguish R&D investment from operational decay — components above tell the real story.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $1.63: Quality below floor (2.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.7/10. Specifically: Below-average business quality; Below long-term trend. Chart setup: RSI 41 mid-range, Bollinger mid-band. Prior stop was $1.52. Score 5.7/10, moderate confidence.
Resistance target: $1.90 (+16.6% upside). Prior stop was $1.52. Stop-loss: $1.52.
DATA_ISSUE: analyst_target_implausible (raw $8.75 vs price $1.63 — ratio 5.4×). Rejected, falling back to technical TP.; Quality below floor (2.2 < 4.0).
Autolus Therapeutics plc trades at a P/E of N/A (forward -2.6). TrendMatrix value score: 7.8/10. Verdict: Sell.
16 analysts cover AUTL with a consensus score of 4.3/5. Average price target: $9.
What does Autolus Therapeutics plc do?Autolus Therapeutics markets AUCATZYL (obe-cel), a CD19-targeted CAR T cell therapy for adult relapsed or refractory...
Autolus Therapeutics markets AUCATZYL (obe-cel), a CD19-targeted CAR T cell therapy for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia, approved by the FDA in November 2024 and launched in the U.S. in January 2025, with the UK's MHRA and the European Commission granting conditional and full marketing authorizations since. The company posted a $287.5 million net loss in 2025 against a $1,386.8 million accumulated deficit, and expects AUCATZYL to generate substantially all of its product revenue for the foreseeable future.